SFPI-FPIM

Tangent Works is a data science startup that specializes in real-time predictive analytics. The company has developed a platform that automates the repetitive and manual tasks typically associated with building predictive models, thus streamlining the work of data scientists. By leveraging advanced machine learning technology, Tangent Works' platform uncovers hidden dynamics within data, providing valuable insights for businesses. Furthermore, it enables the execution of machine learning services directly on devices, facilitating the generation of accurate predictive models specifically tailored for time series analysis. Through its innovative approach, Tangent Works aims to bridge the gap between academic research and practical applications in the industry.

Cohabs operates a network of aesthetically appealing shared homes designed for nomads seeking flexible living arrangements. The company specializes in providing fully furnished co-living spaces that emphasize sustainability and community engagement. Each property is equipped with essential amenities, including weekly cleaning, shared groceries, and utilities, ensuring a comfortable living experience. In addition to housing, Cohabs fosters a vibrant community by organizing monthly events, dinners, and social gatherings, enhancing the overall experience for its residents. This tech-centric approach allows for flexibility and convenience, making it an attractive choice for individuals looking to live in shared environments.

Axelera AI focuses on providing specialized hardware and software platforms to enhance artificial intelligence tasks, particularly in edge computing. Its primary product, the Metis™ AI Platform, combines hardware and software to offer high-performance, energy-efficient AI inference solutions. The platform's innovative design has earned recognition as a CES® 2024 Innovation Awards Honoree. Established in 2021 after incubation by Bitfury and collaboration with imec, Axelera AI is headquartered in the AI Innovation Center at the High Tech Campus in Eindhoven, with research and development offices in Belgium, Switzerland, and Italy. The company's team comprises experts in AI from leading firms and Fortune 500 companies, focusing on delivering sustainable edge applications through a custom dataflow architecture and multicore in-memory computing that minimizes power consumption.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Magnax specializes in yokeless axial flux technology, focusing on high power density solutions for various markets, including electric powertrains and aerospace propulsion systems. The company enhances the capabilities of its subsidiaries, Traxial and Axyal, which target ground-based e-mobility and aerospace, respectively. Magnax's patented manufacturing process incorporates advanced cooling systems for windings, ensuring low stator temperatures and improving the durability of its motors. By utilizing oriented electrical steel, the company reduces core losses, allowing e-mobility businesses to develop lighter and more energy-efficient vehicles.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, focused on developing innovative active immunotherapies for cancer. The company specializes in a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line), which are loaded with cancer-specific antigens to stimulate a robust immune response. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, the company emerged from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. PDC*line Pharma aims to enhance cancer treatment efficacy by producing potent and scalable PDC lines that can boost antitumor responses, including the activation of neoantigens and specific cytotoxic T-cells, offering a more effective alternative to conventional vaccines.

Qpinch is a company that specializes in transforming industrial waste heat into carbon-neutral steam, which can be used to generate electricity and useful process heat. By utilizing their innovative chemical heat transformer, Qpinch helps businesses reduce their energy costs while minimizing their environmental impact. The company's technology is designed to integrate with existing industrial assets, allowing clients to achieve immediate savings on their energy bills. This focus on sustainability and efficiency positions Qpinch as a valuable partner for industries that rely on process heat.

Itsme is a mobile application that provides secure digital authentication services, allowing users to verify their identity and safely engage in online transactions. The platform facilitates a range of functions, including logging in to various digital services, confirming online payments, accessing government applications, and signing official documents electronically. By assigning a unique identification to transactions, Itsme ensures user privacy while navigating online environments. The app is designed to deliver a reliable and user-friendly experience for individuals seeking to manage their digital identities securely.

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Endo Tools Therapeutics S.A. is a medical device company based in Gosselies, Belgium, founded in 2008. The company specializes in the development and manufacture of innovative therapeutic devices for gastroenterologists, focusing on flexible endoscopic interventions. Endo Tools Therapeutics is currently working on a catheter that will enhance therapeutic capabilities in interventional gastroenterology by adding therapeutic channels and degrees of freedom. The company's products aim to address conditions such as obesity, digestive tract tumors, and diabetes, enabling efficient surgical endoscopy through advanced techniques like flexible endoscopic suturing and tissue apposition. Additionally, the company has developed the ENDOMINA platform, which provides gastroenterologists with an open system for performing therapeutic procedures.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.

iTeos Therapeutics is a biopharmaceutical company dedicated to developing immuno-oncology therapies for cancer patients. Founded in 2011, the company operates from headquarters in Cambridge, Massachusetts, and Gosselies, Belgium. iTeos focuses on discovering and advancing small molecule immunomodulators that target the tumor microenvironment, aiming to enhance the body's immune response against cancer. Its pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor, and EOS-448, an antagonist of TIGIT, both currently in Phase 1/2a clinical trials. iTeos' approach is built on the expertise of Ludwig Cancer Research, aiming to improve clinical outcomes by restoring the immune system's ability to fight cancer.

OncoDNA, established by experts with over six decades of combined experience in medical diagnostics, specializes in precision medicine for cancer and genetic diseases. The company offers clinical guidance and real-time monitoring for late-stage cancer patients, aiding clinicians, researchers, and biopharma companies in advancing cancer and genetic disease treatments.

iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established a strong presence in the market with its flagship product, the STARflo glaucoma implant. This non-degradable, micro-porous drainage system reduces intraocular pressure in patients with open-angle glaucoma by enhancing the eye's natural uveoscleral outflow. iSTAR Medical also offers additional products, including STARflo PLUS and STARflo MINI, which provide surgical therapies for glaucoma. The implants are designed to integrate with surrounding tissue, exhibiting anti-fibrotic and anti-inflammatory properties, thereby minimizing complications and the need for medication. The company operates from its eco-friendly R&D and manufacturing facility in Belgium and distributes its products across various international markets, including Australia, China, France, Hungary, Italy, Poland, and Turkey. iSTAR Medical has received multiple quality certifications, including ISO 13485 and ISO 9001, and achieved CE Mark approval for its devices.

Ninepointfive is a venture capital investment firm based in Antwerp, Belgium, founded in 2017. It specializes in co-investing with corporate partners to support technology-based startups from pre-seed funding through to maturity. The firm collaborates with established brands to help founders maximize the value of corporate acceleration. Ninepointfive employs a proprietary methodology that emphasizes speed, growth, and active engagement, ensuring a pragmatic approach to investment. The firm's focus spans various sectors, including energy, financial services, healthcare, information technology, and both B2B and B2C markets.

Unifly is a developer of unmanned traffic management software focused on the secure integration of drones into global airspace. Founded in 2015 by aerospace experts, the company emerged from a vision shared by air traffic controllers who recognized the need for effective management of the increasing number of drones. Unifly's award-winning platform connects authorities and drone operators, allowing for real-time monitoring and management of drone traffic, while providing pilots with essential information regarding the legal status of their flights. The platform is already utilized by national authorities in Germany, Denmark, Austria, and Belgium, and Unifly is also active in the United States and several projects worldwide, including Africa and Asia. By fostering collaboration with various stakeholders, Unifly aims to enhance airspace safety and facilitate the seamless integration of drones into everyday life, addressing critical concerns regarding safety and oversight in both recreational and commercial drone activities.

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Endo Tools Therapeutics S.A. is a medical device company based in Gosselies, Belgium, founded in 2008. The company specializes in the development and manufacture of innovative therapeutic devices for gastroenterologists, focusing on flexible endoscopic interventions. Endo Tools Therapeutics is currently working on a catheter that will enhance therapeutic capabilities in interventional gastroenterology by adding therapeutic channels and degrees of freedom. The company's products aim to address conditions such as obesity, digestive tract tumors, and diabetes, enabling efficient surgical endoscopy through advanced techniques like flexible endoscopic suturing and tissue apposition. Additionally, the company has developed the ENDOMINA platform, which provides gastroenterologists with an open system for performing therapeutic procedures.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

iTeos Therapeutics is a biopharmaceutical company dedicated to developing immuno-oncology therapies for cancer patients. Founded in 2011, the company operates from headquarters in Cambridge, Massachusetts, and Gosselies, Belgium. iTeos focuses on discovering and advancing small molecule immunomodulators that target the tumor microenvironment, aiming to enhance the body's immune response against cancer. Its pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor, and EOS-448, an antagonist of TIGIT, both currently in Phase 1/2a clinical trials. iTeos' approach is built on the expertise of Ludwig Cancer Research, aiming to improve clinical outcomes by restoring the immune system's ability to fight cancer.

Air Belgium S.A., founded in 1979 and based in Mont-Saint-Guibert, Belgium, provides passenger air transportation services primarily between Brussels and Hong Kong. The airline specializes in offering quality, attractively priced intercontinental flights to selected markets in Asia. Its fleet is equipped with economy, premium, and business class seating options, catering to diverse passenger needs, including provisions for traveling with pets and children. Additionally, Air Belgium enhances the travel experience through onboard catering services, ensuring that passengers enjoy comfortable and pleasant journeys.

Synergia Medical, established in 2013 and based in Mont-Saint-Guibert, Belgium, specializes in developing neurostimulation medical devices. The company is renowned for its innovative optoelectronic neurostimulator platform, which integrates biomaterials, optical components, biosensors, and microelectronics. Synergia's mission is to commercialize next-generation neurostimulation devices, led by a seasoned management team with extensive experience in developing implantable neurostimulators. In a short span of three years, the company achieved ISO13485 certification, created and sold an OEM external neurostimulator for a motorized amputee prosthesis arm, and developed its first version of the NAOS platform. Backed by private investors and public research grants, Synergia has grown to a team of thirteen highly skilled multidisciplinary professionals, focusing on advancing medical devices for neurostimulation using optoelectronics.

PharmaFluidics is a spin-off from the Vrije Universiteit Brussel that specializes in developing innovative micro-chip-based chromatography columns for applications in biomarker detection, diagnostics, and drug research and development. The company focuses on creating integrated milli- to nano-engineered solutions tailored for mixing, separation, and reaction processes, leveraging its expertise in chemical engineering and micro-fabrication technology. By providing high-quality, custom solutions, PharmaFluidics aims to enhance the sensitivity and accuracy of detecting active compounds in complex biological samples, including biopsies and proteome digests. This approach supports researchers in their efforts to achieve more effective analytical separations, ultimately benefiting the chemical and life sciences industries.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Ncardia is a biotechnology company focused on expediting the drug discovery and development process. The company leverages human induced pluripotent stem cell (hiPSC) technology to create predictive human cellular assay systems, which are used for safety and efficacy testing of drug candidates. Additionally, Ncardia enhances cardiovascular and neural drug screening, providing researchers and drug discovery companies with tools to better understand human disease biology. This approach aims to accelerate the overall drug discovery process, facilitating the development of safer and more effective therapeutic options.

Ncardia is a biotechnology company focused on expediting the drug discovery and development process. The company leverages human induced pluripotent stem cell (hiPSC) technology to create predictive human cellular assay systems, which are used for safety and efficacy testing of drug candidates. Additionally, Ncardia enhances cardiovascular and neural drug screening, providing researchers and drug discovery companies with tools to better understand human disease biology. This approach aims to accelerate the overall drug discovery process, facilitating the development of safer and more effective therapeutic options.

PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, focused on developing innovative active immunotherapies for cancer. The company specializes in a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line), which are loaded with cancer-specific antigens to stimulate a robust immune response. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, the company emerged from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. PDC*line Pharma aims to enhance cancer treatment efficacy by producing potent and scalable PDC lines that can boost antitumor responses, including the activation of neoantigens and specific cytotoxic T-cells, offering a more effective alternative to conventional vaccines.

iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established a strong presence in the market with its flagship product, the STARflo glaucoma implant. This non-degradable, micro-porous drainage system reduces intraocular pressure in patients with open-angle glaucoma by enhancing the eye's natural uveoscleral outflow. iSTAR Medical also offers additional products, including STARflo PLUS and STARflo MINI, which provide surgical therapies for glaucoma. The implants are designed to integrate with surrounding tissue, exhibiting anti-fibrotic and anti-inflammatory properties, thereby minimizing complications and the need for medication. The company operates from its eco-friendly R&D and manufacturing facility in Belgium and distributes its products across various international markets, including Australia, China, France, Hungary, Italy, Poland, and Turkey. iSTAR Medical has received multiple quality certifications, including ISO 13485 and ISO 9001, and achieved CE Mark approval for its devices.

NovoPolymers NV is a company focused on developing and producing sustainable solutions for the photovoltaic market. It specializes in creating front and back encapsulants designed to protect solar cells, which enhance the power output of both crystalline silicon and thin-film solar modules. By optimizing these encapsulants, NovoPolymers aims to add value throughout the photovoltaic supply chain, contributing to the efficiency and sustainability of solar energy production.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

IBA engages in the distribution of crop protection and cattle feed products.

NovoPolymers NV is a company focused on developing and producing sustainable solutions for the photovoltaic market. It specializes in creating front and back encapsulants designed to protect solar cells, which enhance the power output of both crystalline silicon and thin-film solar modules. By optimizing these encapsulants, NovoPolymers aims to add value throughout the photovoltaic supply chain, contributing to the efficiency and sustainability of solar energy production.

iTeos Therapeutics is a biopharmaceutical company dedicated to developing immuno-oncology therapies for cancer patients. Founded in 2011, the company operates from headquarters in Cambridge, Massachusetts, and Gosselies, Belgium. iTeos focuses on discovering and advancing small molecule immunomodulators that target the tumor microenvironment, aiming to enhance the body's immune response against cancer. Its pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor, and EOS-448, an antagonist of TIGIT, both currently in Phase 1/2a clinical trials. iTeos' approach is built on the expertise of Ludwig Cancer Research, aiming to improve clinical outcomes by restoring the immune system's ability to fight cancer.

NovoPolymers NV is a company focused on developing and producing sustainable solutions for the photovoltaic market. It specializes in creating front and back encapsulants designed to protect solar cells, which enhance the power output of both crystalline silicon and thin-film solar modules. By optimizing these encapsulants, NovoPolymers aims to add value throughout the photovoltaic supply chain, contributing to the efficiency and sustainability of solar energy production.